The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Using BTK inhibitors in patients with underlying cardiac comorbidities
In this video, Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, briefly discusses the cardiovascular toxicity associated with BTK inhibitor (BTKi) therapy and comments on whether these agents can be safely used in patients with underlying cardiac comorbidities. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s a great question. I think that we think that there’s a lot less cardiovascular toxicity that we see with the second generation BTK inhibitors, both acalabrutinib and zanubrutinib. I think that even in patients who have underlying cardiac comorbidities, as long as they are well managed, if a patient has AFib, if it’s controlled on rate control agents or rhythm control agents, and as long as there’s no drug-drug interactions with their cardiac medications I think that we feel comfortable proceeding with BTK inhibitor therapy in this patient population, obviously if they have any side effects or you know concerns we have a higher threshold to investigate that to look into that manage those side effects...
That’s a great question. I think that we think that there’s a lot less cardiovascular toxicity that we see with the second generation BTK inhibitors, both acalabrutinib and zanubrutinib. I think that even in patients who have underlying cardiac comorbidities, as long as they are well managed, if a patient has AFib, if it’s controlled on rate control agents or rhythm control agents, and as long as there’s no drug-drug interactions with their cardiac medications I think that we feel comfortable proceeding with BTK inhibitor therapy in this patient population, obviously if they have any side effects or you know concerns we have a higher threshold to investigate that to look into that manage those side effects. But generally we tend to find these to be very tolerable even in patients with some underlying cardiac comorbidities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
